Parallax Volatility Advisers’s BridgeBio Pharma BBIO Stock Holding History

Parallax Volatility Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-109,700	Closed	-$3.79M	–	1560
2025 Q1	$3.79M	Buy	109,700 +29,000	+36%	+$978K	0.01%	693
2024 Q4	$2.21M	Buy	+80,700	New	+$2.09M	﹤0.01%	1109
2024 Q1	–	Sell	-309,200	Closed	-$12.5M	–	1835
2023 Q4	$12.5M	Buy	309,200 +265,300	+604%	+$7.97M	0.03%	528
2023 Q3	$1.16M	Buy	43,900 +29,000	+195%	+$823K	﹤0.01%	1301
2023 Q2	$256K	Buy	+14,900	New	+$224K	﹤0.01%	1828
2021 Q2	–	Sell	-10,000	Closed	-$616K	–	2987
2021 Q1	$616K	Buy	+10,000	New	+$654K	﹤0.01%	2291

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallax Volatility Advisers's BBIO Position: Q1 2026 in Review

Parallax Volatility Advisers sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 5,538 shares — an estimated $424K sold.

Parallax Volatility Advisers first reported a position in BBIO in Q1 2021 and held it in 9 quarters. The position peaked at $5.29M in Q2 2021. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Parallax Volatility Advisers reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
Parallax Volatility Advisers sold 5,538 BridgeBio Pharma shares in Q1 2026, an estimated $424K.
Parallax Volatility Advisers first reported a position in BridgeBio Pharma in Q1 2021 and held it in 9 quarters.
Parallax Volatility Advisers's BridgeBio Pharma position peaked at $5.29M in Q2 2021.
460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.